Gapping up
In reaction to earnings/guidance:
- CNA +7.9%, ENR +6.6%, L +4.1%, GPN +3.8%, CRNC +3.8%, DNB +3.8%, AMG +3.2%, HAS +2.2%
Other news:
- CRHM +221.1% (to be acquired by Well Health for $4.00 per share, representing aggregate purchase price of ~$292.7 mln and a transaction value of ~$369.2 mln inclusive of credit facility)
- OCGN +70.7% (prices offering of 3 mln shares of common stock at $7.65 per share)
- WPRT +50.4% (Amazon has placed orders for 1,000+ nat gas engines, which will be supplied by a JV between CMI and WPRT)
- SNPR +34.5% (Tortoise Acquisition Corp. II and Volta Industries announce planned merger combined company to remain on the NYSE)
- ARYA +27% (Arya Sciences Acquisition Corp III and Nautilus Biotech entered into a definitive business combination agreement )
- TNXP +24.4% (to develop COVID-19 skin test (tnx-2100) to measure SARS-CoV-2 exposure and t cell immunity)
- CLNE +21.1% (announced that the Los Angeles County Metropolitan Transportation Authority has signed a new agreement for an estimated 47.5 million gallons of its renewable natural gas (RNG) to fuel the nation's largest transit bus fleet)
- VERU +20.3% (announces "positive" efficacy and safety results from a double-blind, randomized, placebo-controlled Phase 2 clinical trial evaluating oral, once-a-day dosing of VERU-111 versus placebo ~40 hospitalized patients at high risk for Acute Respiratory Distress Syndrome from SARS-CoV-2)
- LIZI +17.1% (entered into a cooperation agreement with Horizon Robotics, an established chip maker for smart mobility in China, to collaborate on audio services for the Internet of Vehicles market)
- EBON +10.5% (files for 12,779,553 unit best efforts offering)
- GHVI +10.1% (Gores Holdings VI and Matterport confirm proposed business combination with Gores Holdings VI)
- AVRO +9.6% (announces a 100% reduction, or complete clearance, of toxic substrate in the kidney biopsy of the first patient dosed with the plato gene therapy platform in the ongoing Phase 2 FAB-GTi clinical trial of AVR-RD-01, an investigational ex vivo lentiviral gene therapy for Fabry disease)
- CUB +9.3% (Veritas Capital and Evergreen Coast Capital to acquire Cubic for $70.00 per share; also reported earnings)
- IDYA +7.8% (announces the effectiveness of the Investigational New Drug (IND) application for a Phase 1 clinical trial to evaluate IDE397)
- YY +6.3% (JOYY says sale of YY Live business to Baidu (BIDU) is substantially completed with certain customary matters remaining to be completed in the near future)
- QURE +5.6% (announced that the independent DSMB overseeing the Phase I/II clinical trial of AMT-130 for the treatment of Huntington's disease has met and reviewed the six-month safety data)
- BALY +4.1% (announced that it acquired SportCaller)
- RNLX +3.2% (Renalytix JV Kantaro Biosciences and Atrys Health Partnership Expand Global Footprint of Quantitative COVID-19 Antibody Tests in Europe and South America)
- ZYME +3% (Baker Bros increased passive stake to 9.99%)
- BHVN +2.8% (provides update on ESG practices)
- CMI +2.7% (Amazon has placed orders for 1,000+ nat gas engines, which will be supplied by a JV between CMI and WPRT)
- MTG +2.4% (reports monthly metrics)
- VFF +2.4% (fully repays promissory note related to pure sunfarms acquisition and announces additional investment in Asia-Pacific Partner, Altum)
- PSN +2.4% (announced a multi-award COVID-19 testing indefinite-delivery/indefinite-quantity (IDIQ) contract with a shared ceiling value of $2 billion)
- HIMS +2.3% (files for 174,516,077 share common stock offering by selling shareholders)
- MBRX +2.3% (awarded a grant equivalent to $1.5 mln to the Maria Sklodowska-Curie National Research Institute to fund a Phase 1B/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma (STS) lung metastase)
- CLGN +1.8% (has entered into a worldwide exclusive development and commercialization agreement for dermal and soft tissue filler products with Allergan Aesthetics, an AbbVie (ABBV) company)
- TSLA +1.8% (discloses update to investment policy; says "may invest a portion of such cash in certain alternative reserve assets including digital assets, gold bullion, gold exchange-traded funds and other assets as specified in the future"; says invested $1.5 bln in bitcoin)
- CLSD +1.5% (announced that numerous clinical presentations were delivered at the 44th Virtual Annual Macula Society Meeting)
- TME +1.3% (Spotify discloses 21.1% stake in TME)
Analyst comments:
- TDC +13.9% (upgraded to Buy at B of A; upgraded to Mkt Outperform from Mkt Perform at JMP Securities)
- LYG +2% (upgraded to Neutral from Sell at Goldman)
- EL +1.7% (upgraded to Overweight from Underweight at JP Morgan)
- APD +1.4% (upgraded to Buy from Neutral at BofA Securities)
- TSCO +1.3% (upgraded to Buy from Neutral at Goldman)
- CEQP +1.2% (upgraded to Overweight from Neutral at JP Morgan)
- ABB +1.1% (upgraded to Hold from Sell at Berenberg)
- HSY +0.9% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)